ArticleInternal medicine journal2026
A prospective study of 12-month survival of patients with cirrhosis admitted to intensive care.
Article in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe assessment on whether to escalate care in patients with cirrhosis to the intensive care unit (ICU) is complex, with little data on long-term outcomes. The primary aim of this study was to prospectively examine the ability of liver-specific and ICU prognostic scores to predict 12-month survival among patients with cirrhosis in one non-transplant health service. The secondary aim was to assess the prognostic scores in predicting shorter-term survival and the correlation between other demographic and biochemical factors.
methodsAll patients with cirrhosis who had an unplanned admission to the ICU were included in the study prospectively. Patient demographics and biochemical markers were collected, liver-specific and ICU prognostic scores, as well as the Chronic Liver Failure Consortium acute liver failure and acute decompensation scores were calculated. The pre-acute deterioration Child Turcotte Pugh, Model for End-Stage Liver Disease (MELD) and MELD-Na scores from the 1-6 months prior to the admission were also obtained.
resultsOne hundred patients were included over 33 months, with a median follow-up of 25 months. Sixty percent of patients survived longer than 12 months. Sepsis was the most common cause of cacute on chronic liver failure; (ACLF), which was associated with a lower 30-day survival. Patients with non-variceal gastrointestinal bleeding were more likely to survive 12 months. In patients with ACLF (n = 57), the day 1 MELD score was the best at predicting long-term survival, whereas in patients without ACLF, none of the scores performed particularly well, with an area under the receiver operating characteristic curve below 0.6.
conclusionPatients with cirrhosis may have excellent long-term outcomes following ICU admissions. Distinguishing whether a patient is in ACLF or non-ACLF may aid with determining the appropriate prognostic score to apply to aid decision making on limitations of patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.